Monitor for actual execution of the sale; given the officer's repeated transactions and prior sales, this appears to be part of a planned liquidity strategy rather than a signal of distress. However, continued insider selling could weigh on sentiment if volume accelerates.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $30.44entry
- T+1 · 8mo ago +4.57%α +4.09% · $31.83
- T+5 · 7mo ago −4.86%α −8.48% · $28.96
- T+20 · 7mo ago +38.37%α +28.49% · $42.12
- T+60 · 5mo ago +86.63%α +72.47% · $56.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elizabeth E. Reed, an officer of Travere Therapeutics, filed a Form 144 to notify intent to sell up to 10,000 shares, valued at approximately $300,000 based on current market prices. This follows a series of prior stock option exercises and sales totaling over $1.15 million in the past two months.
Key Facts
- Reporting owner: Elizabeth E. Reed, Officer of Travere Therapeutics
- Shares proposed for sale: 10,000 common shares
- Approximate value of proposed sale: $300,000 (based on $30/share)
- Sale to be conducted through Morgan Stanley Smith Barney LLC
- Recent insider activity includes $1.15M in prior sales by Reed in February–March 2026
Financial Impact
$300,000 proposed sale, part of ongoing insider disposition pattern
Risk Factors
- Perception of insider lack of confidence if selling continues amid flat stock performance
- Potential for increased near-term selling pressure if lock-up periods are expiring or options are vesting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003118 |
| Document: 0001950047-26-003118-index.html | 0001950047-26-003118 |
| Document: 0001950047-26-003118.txt | 0001950047-26-003118 |
Track record
21 reports on TVTX
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers